SAREPTA THERAPEUTICS, INC. Stock-Based Compensation
SAREPTA THERAPEUTICS, INC. (SRPT) reported Stock-Based Compensation of $53.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $24.47M, a 33.90% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $29.40M, a 29.04% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $30.02M, a 39.58% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $14.93M, a 65.65% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $123.40M, a 33.05% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $184.30M, a 0.98% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $182.51M, a 21.67% decline from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $233.02M, a 104.50% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 371 month | Share-based Payment Arrangement, Noncash Expense 374 month | Share-based Payment Arrangement, Noncash Expense 377 month | Share-based Payment Arrangement, Noncash Expense 380 month | Share-based Payment Arrangement, Noncash Expense 383 month | Share-based Payment Arrangement, Noncash Expense 386 month | Share-based Payment Arrangement, Noncash Expense 389 month | Share-based Payment Arrangement, Noncash Expense 392 month | Share-based Payment Arrangement, Noncash Expense 395 month | Share-based Payment Arrangement, Noncash Expense 398 month | Share-based Payment Arrangement, Noncash Expense 401 month | Share-based Payment Arrangement, Noncash Expense 404 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $24.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $53.87M 10-Q · filed 2026-08-05 | $83.89M derived: sum of 3 quarters · filed 2026-08-05 | $98.81M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||||
| 2026-03-31 | $29.40M 10-Q · filed 2026-05-06 | $59.41M derived: sum of 2 quarters · filed 2026-05-06 | $74.34M derived: sum of 3 quarters · filed 2026-05-06 | $111.37M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||||
| 2025-12-31 | $30.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $44.94M derived: sum of 2 quarters · filed 2026-03-02 | $81.97M derived: sum of 3 quarters · filed 2026-08-05 | $123.40M 10-K · filed 2026-03-02 | ||||||||||||
| 2025-09-30 | $14.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $51.95M derived: sum of 2 quarters · filed 2026-08-05 | $93.38M 10-Q · filed 2025-11-06 | $143.06M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||||
| 2025-06-30 | $37.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $78.45M 10-Q · filed 2026-08-05 | $128.13M derived: sum of 3 quarters · filed 2026-08-05 | $171.58M derived: sum of 4 quarters · filed 2026-08-05 | ||||||||||||
| 2025-03-31 | $41.43M 10-Q · filed 2026-05-06 | $91.10M derived: sum of 2 quarters · filed 2026-05-06 | $134.55M derived: sum of 3 quarters · filed 2026-05-06 | $185.04M derived: sum of 4 quarters · filed 2026-05-06 | ||||||||||||
| 2024-12-31 | $49.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $93.13M derived: sum of 2 quarters · filed 2026-03-02 | $143.61M derived: sum of 3 quarters · filed 2026-03-02 | $184.30M 10-K · filed 2026-03-02 | ||||||||||||
| 2024-09-30 | $43.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $93.93M derived: sum of 2 quarters · filed 2025-11-06 | $134.62M 10-Q · filed 2025-11-06 | $180.45M derived: sum of 4 quarters · filed 2026-03-02 | ||||||||||||
| 2024-06-30 | $50.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $91.17M 10-Q · filed 2025-08-06 | $137.00M derived: sum of 3 quarters · filed 2026-03-02 | $185.06M derived: sum of 4 quarters · filed 2026-03-02 | ||||||||||||
| 2024-03-31 | $40.69M 10-Q · filed 2025-05-06 | $86.52M derived: sum of 2 quarters · filed 2026-03-02 | $134.58M derived: sum of 3 quarters · filed 2026-03-02 | $181.96M derived: sum of 4 quarters · filed 2026-03-02 | ||||||||||||
| 2023-12-31 | $45.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $93.89M derived: sum of 2 quarters · filed 2026-03-02 | $141.26M derived: sum of 3 quarters · filed 2026-03-02 | $182.51M 10-K · filed 2026-03-02 | ||||||||||||
| 2023-09-30 | $48.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $95.44M derived: sum of 2 quarters · filed 2024-11-06 | $136.69M 10-Q · filed 2024-11-06 | $187.20M derived: sum of 4 quarters · filed 2025-02-28 | ||||||||||||
| 2023-06-30 | $47.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $88.63M 10-Q · filed 2024-08-07 | $139.14M derived: sum of 3 quarters · filed 2025-02-28 | $189.56M derived: sum of 4 quarters · filed 2025-02-28 | ||||||||||||
| 2023-03-31 | $41.25M 10-Q · filed 2024-05-01 | $91.76M derived: sum of 2 quarters · filed 2025-02-28 | $142.18M derived: sum of 3 quarters · filed 2025-02-28 | $245.07M derived: sum of 4 quarters · filed 2025-02-28 | ||||||||||||
| 2022-12-31 | $50.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $100.93M derived: sum of 2 quarters · filed 2025-02-28 | $203.82M derived: sum of 3 quarters · filed 2025-02-28 | $233.02M 10-K · filed 2025-02-28 | ||||||||||||
| 2022-09-30 | $50.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $153.31M derived: sum of 2 quarters · filed 2023-11-01 | $182.51M 10-Q · filed 2023-11-01 | $212.29M derived: sum of 4 quarters · filed 2024-02-28 | ||||||||||||
| 2022-06-30 | $102.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $132.09M 10-Q · filed 2023-08-02 | $161.87M derived: sum of 3 quarters · filed 2024-02-28 | $188.56M derived: sum of 4 quarters · filed 2024-02-28 | ||||||||||||
| 2022-03-31 | $29.20M 10-Q · filed 2023-05-02 | $58.98M derived: sum of 2 quarters · filed 2024-02-28 | $85.66M derived: sum of 3 quarters · filed 2024-02-28 | $114.63M derived: sum of 4 quarters · filed 2024-02-28 | ||||||||||||
| 2021-12-31 | $29.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $56.47M derived: sum of 2 quarters · filed 2024-02-28 | $85.44M derived: sum of 3 quarters · filed 2024-02-28 | $113.94M 10-K · filed 2024-02-28 | ||||||||||||
| 2021-09-30 | $26.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $55.65M derived: sum of 2 quarters · filed 2022-11-02 | $84.16M 10-Q · filed 2022-11-02 | $113.69M derived: sum of 4 quarters · filed 2023-02-28 | ||||||||||||
| 2021-06-30 | $28.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $57.48M 10-Q · filed 2022-08-02 | $87.00M derived: sum of 3 quarters · filed 2023-02-28 | $113.91M derived: sum of 4 quarters · filed 2023-02-28 | ||||||||||||
| 2021-03-31 | $28.51M 10-Q · filed 2022-05-04 | $58.03M derived: sum of 2 quarters · filed 2023-02-28 | $84.94M derived: sum of 3 quarters · filed 2023-02-28 | $112.55M derived: sum of 4 quarters · filed 2023-02-28 | ||||||||||||
| 2020-12-31 | $29.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $56.43M derived: sum of 2 quarters · filed 2023-02-28 | $84.05M derived: sum of 3 quarters · filed 2023-02-28 | $108.07M 10-K · filed 2023-02-28 | ||||||||||||
| 2020-09-30 | $26.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $54.52M derived: sum of 2 quarters · filed 2021-11-03 | $78.54M 10-Q · filed 2021-11-03 | $100.61M derived: sum of 4 quarters · filed 2022-03-01 | ||||||||||||
| 2020-06-30 | $27.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $51.64M 10-Q · filed 2021-08-04 | $73.70M derived: sum of 3 quarters · filed 2022-03-01 | $94.34M derived: sum of 4 quarters · filed 2022-03-01 | ||||||||||||
| 2020-03-31 | $24.02M 10-Q · filed 2021-05-05 | $46.09M derived: sum of 2 quarters · filed 2022-03-01 | $66.72M derived: sum of 3 quarters · filed 2022-03-01 | $86.49M derived: sum of 4 quarters · filed 2022-03-01 | ||||||||||||
| 2019-12-31 | $22.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $42.70M derived: sum of 2 quarters · filed 2022-03-01 | $62.46M derived: sum of 3 quarters · filed 2022-03-01 | $78.60M 10-K · filed 2022-03-01 | ||||||||||||
| 2019-09-30 | $20.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $40.40M derived: sum of 2 quarters · filed 2020-11-05 | $56.54M 10-Q · filed 2020-11-05 | $69.38M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2019-06-30 | $19.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $35.90M 10-Q · filed 2020-08-05 | $48.74M derived: sum of 3 quarters · filed 2021-03-01 | $60.22M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2019-03-31 | $16.14M 10-Q · filed 2020-05-06 | $28.98M derived: sum of 2 quarters · filed 2021-03-01 | $40.46M derived: sum of 3 quarters · filed 2021-03-01 | $55.74M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2018-12-31 | $12.84M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $24.32M derived: sum of 2 quarters · filed 2021-03-01 | $39.60M derived: sum of 3 quarters · filed 2021-03-01 | $50.13M 10-K · filed 2021-03-01 | ||||||||||||
| 2018-09-30 | $11.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $26.76M derived: sum of 2 quarters · filed 2019-11-07 | $37.29M 10-Q · filed 2019-11-07 | $44.66M derived: sum of 4 quarters · filed 2020-02-26 | ||||||||||||
| 2018-06-30 | $15.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $25.80M 10-Q · filed 2019-08-07 | $33.17M derived: sum of 3 quarters · filed 2020-02-26 | $40.09M derived: sum of 4 quarters · filed 2020-02-26 | ||||||||||||
| 2018-03-31 | $10.53M 10-Q · filed 2019-05-08 | $17.89M derived: sum of 2 quarters · filed 2020-02-26 | $24.81M derived: sum of 3 quarters · filed 2020-02-26 | $35.28M derived: sum of 4 quarters · filed 2020-02-26 | ||||||||||||
| 2017-12-31 | $7.37M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $14.29M derived: sum of 2 quarters · filed 2020-02-26 | $24.75M derived: sum of 3 quarters · filed 2020-02-26 | $30.46M 10-K · filed 2020-02-26 | ||||||||||||
| 2017-09-30 | $6.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $17.39M derived: sum of 2 quarters · filed 2018-10-31 | $23.10M 10-Q · filed 2018-10-31 | $29.97M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||
| 2017-06-30 | $10.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $16.18M 10-Q · filed 2018-08-08 | $23.05M derived: sum of 3 quarters · filed 2019-02-28 | $32.47M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||
| 2017-03-31 | $5.71M 10-Q · filed 2018-05-03 | $12.58M derived: sum of 2 quarters · filed 2019-02-28 | $22.01M derived: sum of 3 quarters · filed 2019-02-28 | $28.84M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||
| 2016-12-31 | $6.87M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $16.30M derived: sum of 2 quarters · filed 2019-02-28 | $23.13M derived: sum of 3 quarters · filed 2019-02-28 | $29.96M 10-K · filed 2019-02-28 | ||||||||||||
| 2016-09-30 | $9.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $16.26M derived: sum of 2 quarters · filed 2017-11-01 | $23.09M 10-Q · filed 2017-11-01 | $29.44M derived: sum of 4 quarters · filed 2018-03-01 | ||||||||||||
| 2016-06-30 | $6.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $13.66M 10-Q · filed 2017-08-03 | $20.01M derived: sum of 3 quarters · filed 2018-03-01 | $25.70M derived: sum of 4 quarters · filed 2018-03-01 | ||||||||||||
| 2016-03-31 | $6.83M 10-Q · filed 2017-05-04 | $13.18M derived: sum of 2 quarters · filed 2018-03-01 | $18.87M derived: sum of 3 quarters · filed 2018-03-01 | $24.80M derived: sum of 4 quarters · filed 2018-03-01 | ||||||||||||
| 2015-12-31 | $6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $12.03M derived: sum of 2 quarters · filed 2018-03-01 | $17.96M derived: sum of 3 quarters · filed 2018-03-01 | $32.12M 10-K · filed 2018-03-01 | ||||||||||||
| 2015-09-30 | $5.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $11.61M derived: sum of 2 quarters · filed 2016-11-07 | $25.77M 10-Q · filed 2016-11-07 | $31.54M derived: sum of 4 quarters · filed 2017-02-28 | ||||||||||||
| 2015-06-30 | $5.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $20.09M 10-Q · filed 2016-08-09 | $25.85M derived: sum of 3 quarters · filed 2017-02-28 | $30.50M derived: sum of 4 quarters · filed 2017-02-28 | ||||||||||||
| 2015-03-31 | $14.16M 10-Q · filed 2016-05-05 | $19.92M derived: sum of 2 quarters · filed 2017-02-28 | $24.57M derived: sum of 3 quarters · filed 2017-02-28 | $30.16M derived: sum of 4 quarters · filed 2017-02-28 | ||||||||||||
| 2014-12-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $10.42M derived: sum of 2 quarters · filed 2017-02-28 | $16.00M derived: sum of 3 quarters · filed 2017-02-28 | $20.34M 10-K · filed 2017-02-28 | ||||||||||||
| 2014-09-30 | $4.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $10.24M derived: sum of 2 quarters · filed 2015-11-05 | $14.58M 10-Q · filed 2015-11-05 | $18.23M derived: sum of 4 quarters · filed 2016-02-25 | ||||||||||||
| 2014-06-30 | $5.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $9.93M 10-Q · filed 2015-08-06 | $13.58M derived: sum of 3 quarters · filed 2016-02-25 | $17.07M derived: sum of 4 quarters · filed 2016-02-25 | ||||||||||||
| 2014-03-31 | $4.34M 10-Q · filed 2015-05-07 | $7.99M derived: sum of 2 quarters · filed 2016-02-25 | $11.48M derived: sum of 3 quarters · filed 2016-02-25 | $13.80M derived: sum of 4 quarters · filed 2016-02-25 | $47.54M 10-Q · filed 2014-05-08 | |||||||||||
| 2013-12-31 | $3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $7.14M derived: sum of 2 quarters · filed 2016-02-25 | $9.46M derived: sum of 3 quarters · filed 2016-02-25 | $11.13M 10-K · filed 2016-02-25 | $43.20M 10-K · filed 2014-03-03 | |||||||||||
| 2013-09-30 | $3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $5.80M derived: sum of 2 quarters · filed 2014-11-06 | $7.48M 10-Q · filed 2014-11-06 | $8.71M derived: sum of 4 quarters · filed 2015-02-26 | $39.55M 10-Q · filed 2013-11-12 | |||||||||||
| 2013-06-30 | $2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $3.99M 10-Q · filed 2014-08-07 | $5.23M derived: sum of 3 quarters · filed 2015-02-26 | $5.92M derived: sum of 4 quarters · filed 2015-02-26 | $36.06M 10-Q · filed 2013-08-08 | |||||||||||
| 2013-03-31 | $1.67M 10-Q · filed 2014-05-08 | $2.91M derived: sum of 2 quarters · filed 2015-02-26 | $3.60M derived: sum of 3 quarters · filed 2015-02-26 | $4.04M derived: sum of 4 quarters · filed 2015-02-26 | $33.74M 10-Q · filed 2013-05-09 | |||||||||||
| 2012-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $1.93M derived: sum of 2 quarters · filed 2015-02-26 | $2.37M derived: sum of 3 quarters · filed 2015-02-26 | $3.08M 10-K · filed 2015-02-26 | $32.07M 10-K · filed 2013-03-15 | |||||||||||
| 2012-09-30 | $692.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $1.13M derived: sum of 2 quarters · filed 2013-11-12 | $1.84M 10-Q · filed 2013-11-12 | $2.52M derived: sum of 4 quarters · filed 2014-03-03 | $30.84M 10-Q · filed 2012-11-07 | |||||||||||
| 2012-06-30 | $440.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $1.15M 10-Q · filed 2013-08-08 | $1.82M derived: sum of 3 quarters · filed 2014-03-03 | $2.42M derived: sum of 4 quarters · filed 2014-03-03 | $30.14M 10-Q · filed 2012-08-07 | |||||||||||
| 2012-03-31 | $708.00K 10-Q · filed 2013-05-09 | $1.38M derived: sum of 2 quarters · filed 2014-03-03 | $1.98M derived: sum of 3 quarters · filed 2014-03-03 | $2.69M derived: sum of 4 quarters · filed 2014-03-03 | $29.70M 10-Q · filed 2012-05-10 | |||||||||||
| 2011-12-31 | $675.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $1.27M derived: sum of 2 quarters · filed 2014-03-03 | $1.98M derived: sum of 3 quarters · filed 2014-03-03 | $3.13M 10-K · filed 2014-03-03 | $29.00M 10-K · filed 2012-03-13 | |||||||||||
| 2011-09-30 | $592.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $1.31M derived: sum of 2 quarters · filed 2012-11-07 | $2.45M 10-Q · filed 2012-11-07 | $3.08M derived: sum of 4 quarters · filed 2013-03-15 | $28.32M 10-Q · filed 2011-11-08 | |||||||||||
| 2011-06-30 | $717.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $1.86M 10-Q · filed 2012-08-07 | $2.49M derived: sum of 3 quarters · filed 2013-03-15 | $3.00M derived: sum of 4 quarters · filed 2013-03-15 | $27.73M 10-Q · filed 2011-08-08 | |||||||||||
| 2011-03-31 | $1.15M 10-Q · filed 2012-05-10 | $1.77M derived: sum of 2 quarters · filed 2013-03-15 | $2.28M derived: sum of 3 quarters · filed 2013-03-15 | |||||||||||||
| 2010-12-31 | $629.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $1.14M derived: sum of 2 quarters · filed 2013-03-15 | $3.17M 10-K · filed 2013-03-15 | |||||||||||||
| 2010-09-30 | $509.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $2.54M 10-Q · filed 2011-11-08 | ||||||||||||||
| 2010-06-30 | $2.03M 10-Q · filed 2011-08-08 | |||||||||||||||
| 2009-12-31 | $2.37M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |